lymphocyte antigen 6 family member KGenealiases: CT97 · HSJ001348 · URLC10 · ly-6K
Q-omics provides the consensus-scored LY6K profile across patient tissues and cancer cell-line models. LY6K expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LY6K is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LY6K RNA expression shows 11,825 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where LY6K shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY6K — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY6K survival associations across molecular data types. LY6K RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY6K RNA expression–survival associations across cancer types. High LY6K expression shows unfavorable associations in KIRC, LUAD, UVM, KIRP and ACC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LY6K RNA expression.
This table summarizes LY6K tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LY6K. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY6K shows lower tumor expression in KIRC and KIRP and higher tumor expression in HNSC, LUAD, BLCA and LUSC. The HNSC box plot shows higher LY6K RNA expression in tumor versus normal tissue (log2 FC = +3.243, t-test p < 0.001).
This table shows molecular features associated with LY6K in patient tissues and cancer cell lines. In patient samples, LY6K shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LY6K RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
